title: Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma).
abstract: Indolent nonfollicular B-cell lymphoma (INFBCL) has been classified in the World Health Organization 2008 system among the mature B-cell neoplasms and includes nodal and extranodal marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), and small lymphocytic lymphoma (SLL). Recently, the array and sequencing technologies have provided new insights into their molecular pathogenesis; the molecular discoveries, however, have not yet translated into consistent changes in their management. Thus, the therapy for INFBCL remains challenging. To promote widespread adoption of appropriate clinical practice, the Italian Society of Hematology and affiliate societies (Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation) reviewed the evidence regarding the management of these lymphomas to produce evidence-based recommendations aimed at contributing to therapy optimization and standardization. We used the Grades of Recommendation, Assessment, Development, and Evaluation system, which is based on a sequential assessment of the quality of evidence, followed by an analysis of the benefit/risk balance and subsequent judgment about the strength of recommendations. For issues without consistent evidence, we used the consensus technique. We have provided separate recommendations for diagnostic and staging requirements, first-line therapy, and postinduction therapy for the most frequent INFBCLs (ie, LPL, SLL, and nodal, splenic, and gastric MZL).
authors.affiliation: Hematology and Cell Therapy Unit, Ospedale Mauriziano and University Department of Biotechnology and Life Science, Torino, Italy.
authors.forename: Corrado
authors.initials: C
authors.lastname: Tarella
authors.affiliation: Department of Hematology Oncology, Fondazione IRCCS Policlinico S. Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Arcaini
authors.affiliation: UO Ematologia CTMO, Fondazione IRCCS, Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milano, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Baldini
authors.affiliation: Biotechnology Research Area, Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: barosig@smatteo.pv.it.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Barosi
authors.affiliation: Unit of Hematology, Ospedale Civile di Bolzano, Bolzano, Italy.
authors.forename: Atto
authors.initials: A
authors.lastname: Billio
authors.affiliation: Unit of Hematology, Ospedale Cardinal Massaia, Asti, Italy.
authors.forename: Monia
authors.initials: M
authors.lastname: Marchetti
authors.affiliation: Division of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.affiliation: Division of Hematology, Azienda Ospedaliera "Città della Salute e della Scienza," Torino, Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Vitolo
authors.affiliation: Institute of Hematology "Seragnoli," University of Bologna, Bologna, Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: University of Bologna, Bologna, Italy.
authors.forename: Sante
authors.initials: S
authors.lastname: Tura
mesh_terms: D016026:Bone Marrow Transplantation / Q000379:methods* / Q000592:standards*; D006405:Hematology / Q000379:methods / Q000592:standards; D006801:Humans; D007558:Italy; D016393:Lymphoma, B-Cell / Q000628:therapy*; D017410:Practice Guidelines as Topic
keywords: FDG-PET; GRADE; Rituximab